摘要
目的:阐明MIC-1在胰腺癌血清学诊断中的价值,初步探讨MIC-1与胰腺癌恶性分化程度、转移等恶性生物学特征的关系。方法:检测MIC-1在胰腺癌、壶腹部恶性肿瘤、胰腺良性病变及健康者外周血中的表达,并同CA19-9、CEA进行比较分析,并比较了MIC-1在Panc-1细胞及BxPc-3细胞中mRNA及蛋白水平的表达。结果:相比健康对照组、胰腺良性肿瘤和慢性胰腺炎人群,胰腺癌患者血清MIC-1水平明显升高,但有14.9%(7/47)的胰腺良性病变患者超过阈值,并没有明显低于CA19-9及CEA。在胰腺癌患者中ROC曲线下面积分别为:MIC-1(0.821)、CA19-9(0.691)、CEA(0.540),MIC-1高于CA19-9及CEA(P<0.05)。MIC-1联合CA19-9可明显提高诊断能力(AUC=0.89,敏感性75.4%,特异性88.8%)。MIC-1在CA19-9阴性胰腺癌患者中敏感性为57.1%。不论在mRNA还是在蛋白表达水平,MIC-1在具有转移癌特征的Panc-1胰腺癌细胞中的表达明显高于具有原发癌特征的BxPc-3胰腺癌细胞。结论:MIC-1可以作为一种理想的胰腺癌的血清学诊断标志物,但是单独使用MIC-1并不能完全区分胰腺癌与胰腺良性病变。MIC-1可能在胰腺癌的发生和进展中扮演重要角色。
Objective:To clarify the value of MIC-1 in serological diagnosis of pancreatic cancer,and to investigate the relationship between MIC-1 and malignant biological characteristics.Method:The expression of MIC-1 in peripheral blood of patients with pancreatic cancer,ampulla malignancies,benign pancreatic lesions and healthy subjects was detected and compared with CA19-9 and CEA,and the expression levels of mRNA and protein of MIC-1 in Panc-1 cells and BxPCc-3 cells were compared.Result:Compared with healthy control,pancreatic benign tumor and chronic pancreatitis group,the level of MIC-1 in pancreatic cancer patients was significantly increased.However,the threshold was exceeded in 14.9% (7/47) patients with benign pancreatic lesions,but not significantly lower than that in CA19-9 and CEA.The area under ROC curve in pancreatic cancer patients was MIC-1 (0.821),CA19-9 (0.691) and CEA (0.540),and MIC-1 was higher than CA19-9 and CEA (P<0.05).MIC-1 combined with CA19-9 significantly improved diagnostic ability (AUC=0.89,sensitivity 75.4%,specificity 88.8%),and the sensitivity of MIC-1 in patients with CA19-9 negative pancreatic cancer was 57.1%.MIC-1 expression in Panc-1 cells was significantly higher than that in BxPc-3 cells.Conclusion:MIC-1 can be used as an ideal serological marker for pancreatic cancer,but MIC-1 cannot completely distinguish pancreatic cancer from benign lesions.MIC-1 may play an important role in the development and progression of pancreatic cancer.
作者
杨新星
李东升
赖亚栋
庄涵虚
YANG Xinxing;LI Dongsheng;LAI Yadong;ZHUANG Hanxu(Zhangzhou Affiliated Hospital of Fujian Medical University,Zhangzhou 363000,China)
出处
《中外医学研究》
2021年第9期83-87,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
漳州市自然科学基金项目(ZZ2012J34)。
